PURPOSE: E-cadherin is a transmembrane glycoprotein, involved in cell-cell adhesion and epithelial-mesenchymal transition (EMT). Vimentin is highly expressed in mesenchymal cells and is positively correlated with increased metastasis. Here we set out to determine the expression of E-cadherin and vimentin in head and neck squamous cell carcinomas (HNSCC). PATIENTS AND METHODS: Twenty-six patients with primary stage II-IV HNSCC were included. E-cadherin and vimentin were visualised using immunohistochemistry, semi-automatically analysed for expression patterns and correlated with the clinical behaviour of these tumours. RESULTS: A large variation in E-cadherin and vimentin expression was observed between tumours (median 17% range 0-51% respectively median 0% range 0-20%). Tumours with low E-cadherin expression showed a significantly higher incidence of metastasis formation compared to tumours with high expression (81% versus 19%, p=0.004). Enhanced expression of vimentin was associated with a trend towards a higher metastatic risk (33% versus 77%) compared to tumours without expression of vimentin. All patients with low E-cadherin and high vimentin expression (an EMT-phenotype) developed distant metastases versus only 44% of the other patients (p=0.008). CONCLUSION: Loss of E-cadherin and gain of vimentin may be associated with enhanced migration of tumour cells, leading to higher metastatic risk of HNSCC patients.
PURPOSE:E-cadherin is a transmembrane glycoprotein, involved in cell-cell adhesion and epithelial-mesenchymal transition (EMT). Vimentin is highly expressed in mesenchymal cells and is positively correlated with increased metastasis. Here we set out to determine the expression of E-cadherin and vimentin in head and neck squamous cell carcinomas (HNSCC). PATIENTS AND METHODS: Twenty-six patients with primary stage II-IV HNSCC were included. E-cadherin and vimentin were visualised using immunohistochemistry, semi-automatically analysed for expression patterns and correlated with the clinical behaviour of these tumours. RESULTS: A large variation in E-cadherin and vimentin expression was observed between tumours (median 17% range 0-51% respectively median 0% range 0-20%). Tumours with low E-cadherin expression showed a significantly higher incidence of metastasis formation compared to tumours with high expression (81% versus 19%, p=0.004). Enhanced expression of vimentin was associated with a trend towards a higher metastatic risk (33% versus 77%) compared to tumours without expression of vimentin. All patients with low E-cadherin and high vimentin expression (an EMT-phenotype) developed distant metastases versus only 44% of the other patients (p=0.008). CONCLUSION: Loss of E-cadherin and gain of vimentin may be associated with enhanced migration of tumour cells, leading to higher metastatic risk of HNSCC patients.
Authors: Marcia S Campos; Kathleen G Neiva; Kristy A Meyers; Sudha Krishnamurthy; Jacques E Nör Journal: Oral Oncol Date: 2011-10-19 Impact factor: 5.337
Authors: Lizandra Jimenez; Jihyeon Lim; Berta Burd; Thomas M Harris; Thomas J Ow; Nicole Kawachi; Thomas J Belbin; Ruth Angeletti; Michael B Prystowsky; Geoffrey Childs; Jeffrey E Segall Journal: Am J Pathol Date: 2017-05-10 Impact factor: 4.307
Authors: Nidhi Bansal; Jade Mims; Jeffrey G Kuremsky; Amy L Olex; Weiling Zhao; Leimiao Yin; Revati Wani; Jiang Qian; Brian Center; Glen S Marrs; Mercedes Porosnicu; Jacquelyn S Fetrow; Allen W Tsang; Cristina M Furdui Journal: Antioxid Redox Signal Date: 2014-04-10 Impact factor: 8.401